Preventing HIV: controversial research must go on

Preventive drug research, even though controversial, 'must go ahead' Copyright: IRD/Michael Wadleigh

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Preventing HIV: controversial research must go on</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p>HIV affects more than 40 million people around the world, yet no HIV vaccine has yet emerged. Now, a drug that could prevent infection with the virus is being tested in Africa, Asia and the United States.</p>
<p>The trials of tenofovir, however, have already hit controversy. Two trials, one in Cambodia and one in Cameroon, were stopped in 2004 and 2005 because of government concerns about their methods. Several ethics issues emerged — for instance, how trial participants were chosen and how access to drugs would be assured after the trials.</p>
<p>In this article, Robert Grant of the Gladstone Institute of Virology and Immunology in San Francisco, United States, and colleagues explain why despite the difficulties in testing them, preventive drugs are a promising approach to tackling HIV/AIDS.</p>
<p>Tenofovir only needs to be taken once a day, and might even provide protection if some doses were missed. In addition, it does not seem to interact with tuberculosis drugs or with hormonal contraceptives, meaning it could be used in high-risk groups.</p>
<p>Grant and colleagues say that community advisors and local ethics review boards must be involved in designing the trial – even before seeking the sponsor’s final approval. The daunting task of providing proven HIV preventive measures to poor countries must also be tackled, they say. But, they stress, a balance must be struck between conducting trials to very high standards and the need to stem the spread of HIV.</p>
<p><a onclick="pageTracker._trackPageview('/tracking/external/'+this.href);" target="_blank" href="/sci.cfm?redir=http://www.sciencemag.org/cgi/content/full/309/5744/2170" rel="noopener noreferrer">Link to article in <em>Science</em></a></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/preventing-hiv-controversial-research-must-go-on/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/preventing-hiv-controversial-research-must-go-on/",null,true])
</script>
</div>

HIV affects more than 40 million people around the world, yet no HIV vaccine has yet emerged. Now, a drug that could prevent infection with the virus is being tested in Africa, Asia and the United States.

The trials of tenofovir, however, have already hit controversy. Two trials, one in Cambodia and one in Cameroon, were stopped in 2004 and 2005 because of government concerns about their methods. Several ethics issues emerged — for instance, how trial participants were chosen and how access to drugs would be assured after the trials.

In this article, Robert Grant of the Gladstone Institute of Virology and Immunology in San Francisco, United States, and colleagues explain why despite the difficulties in testing them, preventive drugs are a promising approach to tackling HIV/AIDS.

Tenofovir only needs to be taken once a day, and might even provide protection if some doses were missed. In addition, it does not seem to interact with tuberculosis drugs or with hormonal contraceptives, meaning it could be used in high-risk groups.

Grant and colleagues say that community advisors and local ethics review boards must be involved in designing the trial – even before seeking the sponsor’s final approval. The daunting task of providing proven HIV preventive measures to poor countries must also be tackled, they say. But, they stress, a balance must be struck between conducting trials to very high standards and the need to stem the spread of HIV.

Link to article in Science